Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

- Ackland, Stephen P., Gebski, V., Forbes, J. F., Coates, A. S., Zdenkowski, N., Wilson, A., Green, M., Tees, S., Dhillon, H., Van Hazel, G., Levi, J., Simes, R. J.

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

- Afentakis, Maria, Dowsett, Mitch, Sestak, Ivana, Salter, Janine, Howell, Tony, Buzdar, Aman, Forbes, John, Cuzick, Jack

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

- Ahearn, Thomas U., Zhang, Haoyu, Michailidou, Kyriaki, Milne, Roger L., Bolla, Manjeet K., Dennis, Joe, Dunning, Alison M., Lush, Michael, Wang, Qin, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Aronson, Kristan J., Auer, Paul L., Augustinsson, Annelie, Baten, Adinda, Becher, Heiko, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Forbes, John, Scott, Rodney

GPU-FS-kNN: a software tool for fast and scalable kNN computation using GPUs

- Arefin, Ahmed Shamsul, Riveros, Carlos, Berretta, Regina, Moscato, Pablo

The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study

- Arriaga, Maria E., Vajdic, Claire M., Shaw, Jonathan E., Gill, Tiffany K., Klaes, Elizabeth, Velentzis, Louiza S., Cumming, Robert G., Hirani, Vasant, Laaksonen, Maarit A., Canfell, Karen, MacInnis, Robert J., Banks, Emily, Byles, Julie E., Magliano, Dianna J., Taylor, Anne W., Mitchell, Paul, Giles, Graham G.

The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer

- Avery-Kiejda, Kelly A., Braye, Stephen G., Forbes, John F., Scott, Rodney J.

The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.

- Avery-Kiejda, Kelly A., Morten, Brianna, Wong-Brown, Michelle W., Mathe, Andrea, Scott, Rodney J.

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer

- Avery-Kiejda, Kelly A., Braye, Stephen G., Mathe, Andrea, Forbes, John F., Scott, Rodney J.

Genome-wide miRNA, gene and methylation analysis of triple negative breast cancer to identify changes associated with lymph node metastases

- Avery-Kiejda, Kelly A., Mathe, Andrea, Scott, Rodney J.

Genetic markers in breast cancer - how far have we come from BRCA1?

- Avery-Kiejda, Kelly A., Wong, Michelle W., Scott, Rodney J.

Antiproliferative and apoptotic effects of the oxidative dimerization product of methyl caffeate on human breast cancer cells

- Bailly, Fabrice, Toillon, Robert-Alain, Tomavo, Olympe, Jouy, Nathalie, Hondermarck, Hubert, Cotelle, Philippe

Design and synthesis of arylhydrocarbon receptor ligands for the treatment of breast cancer

- Baker, Jennifer R.

The aryl hydrocarbon receptor (AhR) as a breast cancer drug target

- Baker, Jennifer R., Sakoff, Jennette A., McCluskey, Adam

Modelling and phenotypic screening of NAP-6 and 10-Cl-BBQ, AhR ligands displaying selective breast cancer cytotoxicity in vitro

- Baker, Jennifer R., Pollard, Brett L., Lin, Andrew J. S., Gilbert, Jayne, Paula, Stefan, Zhu, Xiao, Sakoff, Jennette A., McCluskey, Adam

Amino alcohol acrylonitriles as broad spectrum and tumour selective cytotoxic agents

- Baker, Jennifer R., Russell, Cecilia C., Gilbert, Jayne, McCluskey, Adam, Sakoff, Jennette A.

HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

- Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

- Bernhard, J., Zahrieh, D., Green, M. D., Colleoni, M., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Coates, A. S., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., Forbes, J. F., Aebi, S., Yeo, W., Thurlimann, B.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Carcinoma of the male breast in Zambia

- Bhagwandeen, S. B.

A novel role for brain and acute leukemia cytoplasmic (BAALC) in human breast cancer metastasis

- Birgersson, Madeleine, Chi, Mengna, Miller, Chrissy, Brzozowski, Joshua S., Brown, Jeffrey, Schofield, Lachlan, Taylor, Olivia G., Pearsall, Elizabeth A., Hewitt, Jasmine, Gedye, Craig, Lincz, Lisa F., Skelding, Kathryn A.